1.武汉大学人民医院,妇科,湖北 武汉 430060
2.武汉大学人民医院,对外联络部,湖北 武汉 430060
罗燕,女,1999—,医学硕士生,主要从事妇科肿瘤的研究,E⁃mail:18098911637@163.com
盛恬馨,女,2002—,主要从事妇科肿瘤的研究,E⁃mail:2460825142@qq.com
李新,女,1975—,副教授,主任医师,博士生导师,主要从事妇科疾病的诊治与科研工作,妇科肿瘤的早期诊断及精准靶向、微创治疗,E⁃mail:xin.li@whu.edu.cn
杜勤,女,1976—,主管护师,主要从事医院管理研究,E⁃mail:2430398435@qq.com;罗燕、盛恬馨为本文共同第一作者
收稿:2024-06-16,
纸质出版:2025-04-25
移动端阅览
罗燕,盛恬馨,谷传奇等.KLA多肽对人卵巢癌顺铂耐药细胞的疗效及作用机制[J].武汉大学学报(医学版),2025,46(04):456-462.
LUO Yan,SHENG Tianxin,GU Chuanqi,et al.Efficacy of KLA peptide on cisplatin⁃resistant human ovarian cancer cells and its mechanism[J].Medical Journal of Wuhan University,2025,46(04):456-462.
罗燕,盛恬馨,谷传奇等.KLA多肽对人卵巢癌顺铂耐药细胞的疗效及作用机制[J].武汉大学学报(医学版),2025,46(04):456-462. DOI: 10.14188/j.1671-8852.2024.0456.
LUO Yan,SHENG Tianxin,GU Chuanqi,et al.Efficacy of KLA peptide on cisplatin⁃resistant human ovarian cancer cells and its mechanism[J].Medical Journal of Wuhan University,2025,46(04):456-462. DOI: 10.14188/j.1671-8852.2024.0456.
目的
2
探究一种阳离子两亲性多肽KLA对卵巢癌细胞系的治疗作用及其相关机制,以期为后续抗癌药物的研发提供新的思路。
方法
2
合成KLA后,在不同浓度下分别与正常细胞、肿瘤细胞和肿瘤耐药细胞共培养,并与相同质量浓度顺铂处理下的细胞进行细胞活力比较;用流式细胞仪分别测得KLA处理下耐药细胞的凋亡水平、活性氧水平及细胞周期;对线粒体进行JC⁃1染色,探究KLA对线粒体膜电位的影响。
结果
2
KLA处理红细胞溶血率趋近于0;KLA对SKOV3、SKOV3/DDP、MRC⁃5细胞的半数抑制浓度(IC
50
)分别为21.99
15.33
166.2 μg⋅mL
-1
,顺铂对SKOV3、SKOV3/DDP、MRC⁃5细胞的IC
50
分别为15.24
43.85
85.62 μg⋅mL
-1
;KLA处理后SKOV3细胞凋亡水平由7.7%提高到了27.3%,SKOV3/DDP细胞由4.2%提高到了51.1%,A2780细胞的凋亡水平由5.0%提高到14.7%,A2780/DDP细胞凋亡水平由6.0%提高到46.8%;KLA对SKOV3、SKOV3/DDP细胞周期无显著影响;在JC⁃1染色中,KLA降低了SKOV3和SKOV3/DDP细胞内线粒体膜电位;KLA提高了SKOV3和SKOV3/DDP细胞内ROS的水平。
结论
2
KLA多肽能够通过损伤线粒体膜电位、增加细胞内活性氧水平等方式,引发胞内氧化应激,促进细胞凋亡,且对肿瘤耐药细胞具有更强作用。
Objective
2
To investigate the therapeutic effects and mechanisms of a cationic amphiphilic peptide KLA on ovarian cancer cell lines and to provide new insights for the development of anticancer drugs.
Methods
2
KLA was synthesized and co⁃cultured with normal cells
tumor cells
and drug⁃resistant tumor cells at various concentrations. Cell viability was compared with cells treated with cisplatin at the same concentration. Flow cytometry was used to measure the apoptosis levels
reactive oxygen species (ROS) levels
and cell cycle of drug⁃resistant cells treated with KLA. JC⁃1 staining was used to examine the effects of KLA on mitochondrial membrane potential.
Results
2
The hemolysis rate of erythrocytes treated with KLA was nearly 0. The half maximal inhibitory concentration (IC
50
) values of KLA for SKOV3
SKOV3/DDP
and MRC⁃5 cells were 21.99
15.33
and 166.2 μg⋅mL
-1
respectively
whereas the IC
50
values of cisplatin for SKOV3
SKOV3/DDP
and MRC⁃5 cells were 15.24
43.85
and 85.62 μg⋅mL
-1
respectively. KLA treatment increased the apoptosis level in SKOV3 cells from 7.7% to 27.3%
in SKOV3/DDP cells from 4.2% to 51.1%
in A2780 cells from 5.0% to 14.7%
and in A2780/DDP cells from 6.0% to 46.8%. KLA had no significant effect on the cell cycle of SKOV3 and SKOV3/DDP cells. JC⁃1 staining showed that KLA reduced the mitochondrial membrane potential in SKOV3 and SKOV3/DDP cells. KLA increased ROS levels in SKOV3 and SKOV3/DDP cells.
Conclusion
2
KLA peptide can induce oxidative stress
promote apoptosis by damaging mitochondrial membrane potential
and increase intracellular ROS levels
with a stronger effect on drug⁃resistant tumor cells.
KUROKI L , GUNTUPALLI S R . Treatment of epithelial ovarian cancer [J ] . BMJ , 2020 , 371 : m3773 .
WANG Z , MENG F H , ZHONG Z Y . Emerging targeted drug delivery strategies toward ovarian cancer [J ] . Adv Drug Deliv Rev , 2021 , 178 : 113969 .
YANG L , XIE H J , LI Y Y , et al . Molecular mechanisms of platinum⁃based chemotherapy resistance in ovarian cancer (Review) [J ] . Oncol Rep , 2022 , 47 ( 4 ): 82 .
MAGANA M , PUSHPANATHAN M , SANTOS A L , et al . The value of antimicrobial peptides in the age of resistance [J ] . Lancet Infect Dis , 2020 , 20 ( 9 ): e216 ⁃e230.
LATH A , SANTAL A R , KAUR N , et al . Anti⁃cancer peptides: Their current trends in the development of peptide⁃based therapy and anti⁃tumor drugs [J ] . Biotechnol Genet Eng Rev , 2023 , 39 ( 1 ): 45 ⁃ 84 .
LI C M , HARATIPOUR P , LINGEMAN R G , et al . Novel peptide therapeutic approaches for cancer treatment [J ] . Cells , 2021 , 10 ( 11 ): 2908 .
KARAMI FATH M , BABAKHANIYAN K , ZOKAEI M , et al . Anti⁃cancer peptide⁃based therapeutic strategies in solid tumors [J ] . Cell Mol Biol Lett , 2022 , 27 ( 1 ): 33 .
JAVADPOUR M M , JUBAN M M , LO W C , et al . De novo antimicrobial peptides with low mammalian cell toxicity [J ] . J Med Chem , 1996 , 39 ( 16 ): 3107 ⁃ 3113 .
ABNOUS K , DANESH N M , RAMEZANI M , et al . A smart ATP⁃responsive chemotherapy drug⁃free delivery system using a DNA nanostructure for synergistic treatment of breast cancer in vitro and in vivo [J ] . J Drug Target , 2020 , 28 ( 7/8 ): 852 ⁃ 859 .
TAVAKOLI S , FIROOZPOUR L , DAVOODI J . The synergistic effect of chimeras consisting of N⁃terminal smac and modified KLA peptides in inducing apoptosis in breast cancer cell lines [J ] . Biochem Biophys Res Commun , 2023 , 655 : 138 ⁃ 144 .
WAN X , WANG W S , ZHOU Y T , et al . Self⁃delivery nanoplatform based on amphiphilic apoptosis peptide for precise mitochondria⁃targeting photothermal therapy [J ] . Mol Pharm , 2024 , 21 ( 3 ): 1537 ⁃ 1547 .
SONG M D , CUI M X , LIU K H . Therapeutic strategies to overcome cisplatin resistance in ovarian cancer [J ] . Eur J Med Chem , 2022 , 232 : 114205 .
MANSUR A A P , PAIVA M R B , Cotta OAL , et al . Carboxymethylcellulose biofunctionalized ternary quantum dots for subcellular⁃targeted brain cancer nanotheranostics [J ] . Int J Biol Macromol , 2022 , 210 : 530 ⁃ 544 .
HE X D , ZHANG F , HUANG Y , et al . Potential indicators of mitochondrial structure and function [J ] . Curr Pharm Des , 2022 , 28 ( 21 ): 1738 ⁃ 1744 .
MAHMOOD A , BISOYI P , BANERJEE R , et al . Mitoapocynin, a mitochondria targeted derivative of apocynin induces mitochondrial ROS generation and apoptosis in multiple cell types including cardiac myoblasts: A potential constraint to its therapeutic use [J ] . Mol Cell Biochem , 2021 , 476 ( 5 ): 2047 ⁃ 2059 .
0
浏览量
123
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621